Companies /Healthcare

Nurix Therapeutics Inc

NASDAQ: NRIX Biotechnology
$26.72
▼ $0.23 (−0.85%) today
Markets open · 3:26pm ET

Q1 2026 Earnings

Reported Apr 8, 2026, 6:02am ET · SEC source
$-0.79
Miss −3.32%
EPS · est. $-0.76
$6.3M
Miss −56.09%
Revenue · est. $14.2M
−3.2%
Trailing market
NRIX vs S&P since report
2 quarters
Consecutive EPS misses

Market Reaction

% change · around the report
−12%−8%−4%0Apr 8Apr 9report 6:02am ETearnings+0.6%−8.7%
−12%−8%−4%0Apr 8Apr 9earnings+0.6%−8.7%
NRIX −8.7%S&P 500 +0.6%
−12%−8%−4%0Apr 8Apr 9report 6:02am ETearnings+0.2%−8.7%
−12%−8%−4%0Apr 8Apr 9earnings+0.2%−8.7%
NRIX −8.7%NASDAQ +0.2%
−4%0+4%Apr 7Apr 16report 6:02am ETearnings+3.5%+1.6%
−4%0+4%Apr 7Apr 16earnings+3.5%+1.6%
NRIX +1.6%S&P 500 +3.5%
−4%0+4%Apr 7Apr 16report 6:02am ETearnings+4.9%+1.6%
−4%0+4%Apr 7Apr 16earnings+4.9%+1.6%
NRIX +1.6%NASDAQ +4.9%
−4.59%
Day of report
+4.10%
Next session
+8.78%
One week
+5.90%
30 days

S&P 500 over the same 30 days: +9.11%.

Did NRIX Beat Earnings? Q1 2026 Results

Nurix Therapeutics delivered a disappointing fiscal first quarter, missing on both the top and bottom lines as collaboration revenue collapsed 66.1% year-over-year to $6.25 million, well short of the $14.24 million consensus, while its loss per share of $0.79 edged past the $0.76 estimate by 3.32%. The sharp revenue decline was driven primarily by the expiration of the initial research term for certain drug targets under the company's Sanofi collaboration, which had contributed meaningfully to the year-ago period's $18.45 million. Research and development expenses climbed to $84.14 million from $69.66 million as Nurix accelerated enrollment in its Phase 2 DAYBreak CLL-201 pivotal trial and ramped contract manufacturing, widening the net loss to $87.17 million. Despite the headline misses, shares rose roughly 9% in the aftermath, with investors appearing to look past near-term financials toward the planned mid-2026 launch of the global Phase 3 DAYBreak CLL-306 confirmatory trial and a 2026 IND submission targeting autoimmune indications; the company held $540.73 million in cash and equivalents to fund that path.

Key Takeaways
  • Decline in Sanofi collaboration revenue as initial research term for certain drug targets ended
  • Increased R&D spending driven by clinical acceleration of bexobrutideg Phase 2 enrollment and Phase 3 enablement
  • Higher compensation and personnel costs across R&D and G&A functions

“Nurix entered 2026 focused on implementing a comprehensive registrational program designed to establish bexobrutideg as a potential best-in-class medicine for patients with chronic lymphocytic leukemia.”

Nurix Therapeutics CEO, on the earnings call

Forward Guidance & Outlook

Nurix plans to initiate the global randomized confirmatory Phase 3 DAYBreak CLL-306 trial by mid-2026 comparing bexobrutideg monotherapy to pirtobrutinib in r/r CLL. The company is targeting a 2026 IND submission for bexobrutideg in inflammatory and autoimmune indications using a new tablet formulation. Updated clinical data from the Phase 1a/1b NX-5948-301 study are expected at medical meetings throughout 2026. Nurix anticipates the achievement of substantial research collaboration milestones throughout the terms of its collaborations with Gilead, Sanofi, and Pfizer.

NRIX YoY Financials

Q1 2026 vs Q1 2025 · SEC filings Q1 2025 Q1 2026
$-210,000,000$-140,000,000$-70,000,000$0$18.5M$6.3MRevenue$-174,981,082$-92,495,000Operating Income$-192,437,086$-87,174,000Net Income
$-210,000,000$-140,000,000$-70,000,000$0RevenueOperating IncomeNet Income

NRIX Revenue by Segment

License Revenue
Collaboration Revenue$6.3M

Figures from SEC filings and company reports. Not investment advice.